Corporate Finance

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

A blockbuster drug for chronic illness gets a generic rival, promising huge savings. But is it just about price? A deep dive into the strategy behind the new pill.

As J.B. Hunt executives prepare to address a key investor conference, all eyes are on their strategy for intermodal dominance and digital freight innovation.

Beyond a simple Father's Day gift, the St. Regis and Drake's partnership reveals a savvy strategy for experiential luxury and market expansion. Here's how.

San Francisco startup Krane is launching its Procurement OS, using live data and AI to predict supply chain risks months in advance, aiming to end costly delays.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

While media giants crumble under VC pressure, a bootstrapped newsletter hits a $101M valuation. Is 1440's quiet, profitable model the answer?

Beyond greenwashing, the animal health giant's latest report reveals a calculated strategy where innovation, philanthropy, and climate action drive market leadership.

Independent validation from Nucleus Research confirms Zebra Technologies' leadership, but the real story is how its AI tools translate into profit and retention.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

Lamb Weston's closure of a Dutch plant isn't just a local story. It's a calculated move in a global strategy to boost efficiency and tech adoption.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

NTT DATA's top ranking in agentic AI reveals a market pivot from pilot projects to production-ready systems, solving the 'pilot paralysis' plaguing enterprises.

A Florida biotech is using a novel gene therapy to correct aging-related errors. But the real story is its funding: a decentralized, crypto-style model.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

Spanish immersion leader Tierra Encantada adds a heavy-hitter to its board. What does this strategic move say about scaling a mission-driven franchise?

A fully funded drill program in Saskatchewan's rich Athabasca Basin showcases a clever partnership and the urgent, global race for clean nuclear energy.

Global consulting firm Protiviti secures a patent for an AI system that automates tedious compliance questionnaires, but its true innovation is keeping humans in control.

A new study reveals a vast spending gap across the GTHA. Is Toronto's high tab a sign of value or inefficiency? A look at the systems behind the numbers.

As CEO Vytautas Sinius delivers a final address, investors are looking past his legacy to the future under his successor, CFO Tomas Varenbergas.